Neurochemical dysfunction in treated and nontreated schizophrenia-A retrospective analysis of in vivo imaging studies

Reviews in the Neurosciences

Volumn 25, Issue 1, 2014, Pages 25-96

  Nikolaus, Susanne ^a   Hautzel, Hubertus ^a   Müller, Hans Wilhelm ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

dopamine; GABA; PET; schizophrenia; serotonin; SPECT

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; AMINO ACID RECEPTOR; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE AUTORECEPTOR; DOPAMINE AUTORECEPTOR 2; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR 2; DOPAMINE TRANSPORTER; ENDOCANNABINOID; GLUTAMIC ACID; HISTAMINE; MU AMINO BUTYRIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; UNCLASSIFIED DRUG;

ANALYSIS OF VARIANCE; ARTICLE; BINDING SITE; CORPUS STRIATUM; DESENSITIZATION; DOPAMINE METABOLISM; DOPAMINE RELEASE; FRONTAL CORTEX; HUMAN; IMAGE ANALYSIS; IN VIVO STUDY; NEGATIVE FEEDBACK; NEOSTRIATUM; NEUROCHEMICAL DYSFUNCTION; NEUROLOGIC DISEASE; NONHUMAN; PARIETAL CORTEX; POSITIVE SYNDROME; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SENSITIZATION; TEMPORAL CORTEX; THALAMUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; HUMANS; NEUROIMAGING; NEUROTRANSMITTER AGENTS; PUBMED; RETROSPECTIVE STUDIES; SCHIZOPHRENIA;

EID: 84896764641     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/revneuro-2013-0063     Document Type: Article

References (256)

1. Abi-Dargham, A. (2003). Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us World Psychiatry 2, 166-171.
2. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., van Dyck, C.H., Charney, D.S., Innis, R.B., and Laruelle, M. (1998). Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am. J. Psychiatry 155, 761-767. (Pubitemid 28252654)
3. Abi-Dargham, A., Laruelle, M., Krystal, J., D'Souza, C., Zoghbi, S., Baldwin, R.M., Seibyl, J., Mawlawi, O., de Erasquin, G., Charney, D., et al. (1999). No evidence of altered in vivo benzodiazepine receptor binding in schizophrenia. Neuropsychopharmacology 20, 650-661. (Pubitemid 29189268)
4. Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L.S., Weiss, R., Cooper, T.B., Mann, J.J., Van Heertum, R.L., et al. (2000). Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA 97, 8104-8109. (Pubitemid 30460780)
5. Abi-Dargham, A., Mawlawi, O., Lombardo, I., Gil, R., Martinez, D., Huang, Y., Hwang, D.R., Keilp, J., Kochan, L., Van Heertum, R., et al. (2002). Prefrontal dopamine D1 receptors and working memory in schizophrenia. J. Neurosci. 22, 3708-3719. (Pubitemid 37465776)
6. Abi-Dargham, A., Kegeles, L.S., Zea-Ponce, Y., Mawlawi, O., Martinez, D., Mitropoulou, V., O'Flynn, K., Koenigsberg, H.W., Van Heertum, R., Cooper, T., et al. (2004). Striatal amphetamine-induced dopamine release in patients with schizotypal personality disorder studied with single photon emission computed tomography and [123I]iodobenzamide. Biol. Psychiatry 55, 1001-1006. (Pubitemid 38584612)
7. Abi-Dargham, A., van de Giessen, E., Slifstein, M., Kegeles, L.S., and Laruelle, M. (2009). Baseline and amphetamine-stimulated dopamine activity are related in drug-nae schizophrenic subjects. Biol. Psychiatry 65, 1091-1093.
8. Abi-Dargham, A., Xu, X., Thompson, J.L., Gil, R., Kegeles, L.S., Urban, N., Narendran, R., Hwang, D.R., Laruelle, M., and Slifstein, M. (2012). Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [C]NNC112. J. Psychopharmacol. 26, 794-805.
9. Abi-Saab, W.M., Bubser, M., Roth, R.H., and Deutch, A.Y. (1999). 5-HT2 receptor regulation of extracellular GABA levels in the prefrontal cortex. Neuropsychopharmacology 20, 92-96. (Pubitemid 29010343)
10. Agid, O., Mamo, D., Ginovart, N., Vitcu, I., Wilson, A.A., Zipursky, R.B., and Kapur, S. (2007). Striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response-a double-blind PET study in schizophrenia. Neuropsychopharmacology 32, 1209-1215. (Pubitemid 46788848)
11. Alex, K.D. and Pehek, E.A. (2007). Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission. Pharmacol. Ther. 113, 296-320. (Pubitemid 46149046)
12. Allen, A.T., Maher, K.N., Wani, K.A., Betts, K.E., and Chase, D.L. (2011). Coexpressed D1-and D2-like dopamine receptors antagonistically modulate acetylcholine release in Caenorhabditis elegans. Genetics 188, 579-590.
13. Arakawa, R., Ichimiya, T., Ito, H., Takano, A., Okumura, M., Takahashi, H., Takano, H., Yasuno, F., Kato, M., Okubo, Y., et al. (2009). Increase in thalamic binding of [(11)C]PE2I in patients with schizophrenia: a positron emission tomography study of dopamine transporter. J. Psychiatr. Res. 43, 1219-1223.
14. Arakawa, R., Ito, H., Okumura, M., Takano, A., Takahashi, H., Takano, H., Okubo, Y., and Suhara, T. (2010). Extrastriatal dopamine D(2) receptor occupancy in olanzapine-treated patients with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 260, 345-350.
15. Ball, S., Busatto, G.F., David, A.S., Jones, S.H., Hemsley, D.R., Pilowsky, L.S., Costa, D.C., Ell, P.J., and Kerwin, R.W. (1998). Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: a 123I-iomazenil SPET study. Biol. Psychiatry 43, 107-117. (Pubitemid 28079080)
16. Bantick, R.A., Montgomery, A.J., Bench, C.J., Choudhry, T., Malek, N., McKenna, P.J., Quested, D.J., Deakin, J.F., and Grasby, P.M. (2004). A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J. Psychopharmacol. 18, 346-354. (Pubitemid 39386285)
17. Barnas, C., Quiner, S., Tauscher, J., Hilger, E., Willeit, M., Kferle, B., Asenbaum, S., Brke, T., Rao, M.L., and Kasper, S. (2001). In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology (Berl) 157, 236-242. (Pubitemid 32905564)
18. Benes, F.M. and Berretta, S. (2001). GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1-27. (Pubitemid 32493819)
19. Bertolino, A. and Blasi, G. (2009). The genetics of schizophrenia. Neuroscience 164, 288-299.
20. Bertolino, A., Breier, A., Callicott, J.H., Adler, C., Mattay, V.S., Shapiro, M., Frank, J.A., Pickar, D., and Weinberger, D.R. (2000). The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology 22, 125-132. (Pubitemid 30016014)
21. Best, J., Nijhout, H.F., and Reed, M. (2010). Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theor. Biol. Med. Model 7, 34.
22. Bigliani, V. and Pilowsky, L.S. (1999). In vivo neuropharmacology of schizophrenia. Br. J. Psychiatry Suppl. 38, 23-33. (Pubitemid 29230047)
23. Bigliani, V., Mulligan, R.S., Acton, P.D., Visvikis, D., Ell, P.J., Stephenson, C., Kerwin, R.W., and Pilowsky, L.S. (1999). In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs [123I]epidepride single photon emission tomography (SPET) study. Br. J. Psychiatry 175, 231-238. (Pubitemid 29406592)
24. Bose, S.K., Turkheimer, F.E., Howes, O.D., Mehta, M.A., Cunliffe, R., Stokes, P.R., and Grasby, P.M. (2008). Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging. Schizophr. Res. 106, 148-515.
25. Brasic, J.R., Cascella, N., Kumar, A., Zhou, Y., Hilton, J., Raymont, V., Crabb, A., Guevara, M.R., Horti, A.G., and Wong, D.F. (2012). Positron emission tomography experience with 2-[18F]fluoro-3-(2(S)-azetidinylmethoxy)pyridine (2-[18F]FA) in the living human brain of smokers with paranoid schizophrenia. Synapse 66, 352-368.
26. Breier, A., Su, T.P., Saunders, R., Carson, R.E., Kolachana, B.S., de Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K., Eckelman, W.C., et al. (1997). Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. USA 94, 2569-7254.
27. Bressan, R.A., Erlandsson, K., Mulligan, R.S., Gunn, R.N., Cunningham, V.J., Owens, J., Ell, P.J., and Pilowsky, L.S. (2003). Evaluation of NMDA receptors in vivo in schizophrenic patients with [123I]CNS 1261 and SPET: preliminary findings. Ann. N. Y. Acad. Sci. 1003, 364-367. (Pubitemid 38083072)
28. Bressan, R.A., Erlandsson, K., Stone, J.M., Mulligan, R.S., Krystal, J.H., Ell, P.J., and Pilowsky, L.S. (2005). Impact of schizophrenia and chronic antipsychotic treatment on [123I] CNS-1261 binding to N-methyl-D-aspartate receptors in vivo. Biol. Psychiatry 58, 41-46. (Pubitemid 40909934)
29. Brown, A.S. (2011). The environment and susceptibility to schizophrenia. Prog. Neurobiol. 93, 23-58.
30. Brücke, T., Wenger, S., Podreka, I., and Asenbaum, S, (1991). Dopamine receptor classification, neuroanatomical distribution and in vivo imaging. Wien Klin. Wochenschr. 103, 639-646.
31. Buchsbaum, M.S., Christian, B.T., Lehrer, D.S., Narayanan, T.K., Shi, B., Mantil, J., Kemether, E., Oakes, T.R., and Mukherjee, J. (2006). D2/D3 dopamine receptor binding with [F-18]fallypride in thalamus and cortex of patients with schizophrenia. Schizophr. Res. 85, 232-244. (Pubitemid 43947535)
32. Busatto, G.F., Pilowsky, L.S., Costa, D.C., Ell, P.J., David, A.S., Lucey, J.V., and Kerwin, R.W. (1997). Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia. Am. J. Psychiatry 154, 56-63. (Pubitemid 27020193)
33. Bymaster, F.P., Felder, C., Ahmed, S., and McKinzie, D. (2002). Muscarinic receptors as a target for drugs treating schizophrenia. Curr. Drug Targets CNS Neurol. Disord. 1, 163-181.
34. Cadogan, A.K., Alexander, S.P., Boyd, E.A., and Kendall, D.A. (1997). Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. J. Neurochem. 69, 1131-1137. (Pubitemid 27364833)
35. Carey, R.J., Pinheiro-Carrera, M., Tomaz, C., and Huston, J.P. (1994). Early L-DOPA treatment initially retards but later enhances dopamine receptor supersensitivity following unilateral dopamine denervation. Brain Res. 658, 145-154. (Pubitemid 24291713)
36. Castagnini, A. and Berrios, G.E. (2009). Acute and transient psychotic disorders (ICD-10 F23): a review from a European perspective. Eur. Arch. Psychiatry Clin. Neurosci. 259, 433-443.
37. Catafau, A.M., Suarez, M., Bullich, S., Llop, J., Nucci, G., Gunn, R.N., Brittain, C., Laruelle, M.; Barcelona Clinical Imaging in Psychiatry Group. (2009). Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET. Neuroimage 46, 447-458.
38. Catafau, A.M., Bullich, S., Nucci, G., Burgess, C., Gray, F., Merlo-Pich, E.; Barcelona Clinical Imaging in Psychiatry Group. (2011). Contribution of SPECT measurements of D2 and 5-HT2A occupancy to the clinical development of the antipsychotic SB-773812. J. Nucl. Med. 52, 526-534.
39. Chabrol, H. (2003). Chronic hallucinatory psychosis, bouffée délirante, and the classification of psychosis in French psychiatry. Curr. Psychiatry Rep. 5, 187-191. (Pubitemid 38914994)
40. Chen, N. and Reith, M.E. (2000). Structure and function of the dopamine transporter. Eur. J. Pharmacol. 405, 329-339.
41. Chen, K.C., Yang, Y.K., Howes, O., Lee, I.H., Landau, S., Yeh, T.L., Chiu, N.T., Chen, P.S., Lu, R.B., David, A.S., et al. (2013). Striatal dopamine transporter availability in drug-naive patients with schizophrenia: a case-control SPECT study with [(99m) Tc]-TRODAT-1 and a meta-analysis. Schizophr. Bull. 39, 378-386.
42. Cherlyn, S.Y., Woon, P.S., Liu, J.J., Ong, W.Y., Tsai, G.C., and Sim, K. (2010). Genetic association studies of glutamate, GABA and related genes in schizophrenia and bipolar disorder: a decade of advance. Neurosci. Biobehav. Rev. 34, 958-977.
43. Chiodo, A.L., Freeman, A.S., and Bunney, B.S. (1995). Dopamine Autoreceptor Signal Transduction and Regulation. Psychopharmacology-The Fourth Generation of Progress. F.E. Bloom and D.J. Kupfer, eds. (New York: Raven Press), pp. 221-226.
44. Clow, D.W. and Jhamandas, K. (1989). Characterization of L-glutamate action on the release of endogenous dopamine from the rat caudate-putamen. J. Pharmacol. Exp. Ther. 248, 722-728. (Pubitemid 19090245)
45. Corripio, I., Pérez, V., Catafau, A.M., Mena, E., Carrió, I., and Alvarez, E. (2006). Striatal D2 receptor binding as a marker of prognosis and outcome in untreated first-episode psychosis. Neuroimage 29, 662-666. (Pubitemid 43063323)
46. Corripio, I., Escartí, M.J., Portella, M.J., Pérez, V., Grasa, E., Sauras, R.B., Alonso, A., Safont, G., Camacho, M.V., Dueñas, R., et al. (2011). Density of striatal D2 receptors in untreated first-episode psychosis: an I123-IBZM SPECT study. Eur. Neuropsychopharmacol. 21, 861-816.
47. Costa, A., Riedel, M., Müller, U., Möller, H.J., and Ettinger, U. (2011). Relationship between SLC6A3 genotype and striatal dopamine transporter availability: a meta-analysis of human single photon emission computed tomography studies. Synpase 65, 998-1005.
48. Coyle, J.T. (2004). The GABA-glutamate connection in schizophrenia: which is the proximate cause Biochem. Pharmacol. 68, 1507-1514. (Pubitemid 39286454)
49. Coyle, J.T. and Tsai, G. (2004). The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia. Psychopharmacology (Berl) 174, 32-38. (Pubitemid 38925088)
50. Cozzi, N.V. and Nichols, D.E. (1996). 5-HT2A receptor antagonists inhibit potassium-stimulated γ-aminobutyric acid release in rat frontal cortex. Eur. J. Pharmacol. 309, 25-31. (Pubitemid 26253013)
51. Crawley, J.C., Owens, D.G., Crow, T.J., Poulter, M., Johnstone, E.C., Smith, T., Oldland, S.R., Veall, N., Owen, F., and Zanelli, G.D. (1986a). Dopamine D2 receptors in schizophrenia studied in vivo. Lancet 2, 224-225. (Pubitemid 16059433)
52. Crawley, J.C., Crow, T.J., Johnstone, E.C., Oldland, S.R., Owen, F., Owens, D.G., Smith, T., Veall, N., and Zanelli, G.D. (1986b). Uptake of 77Br-spiperone in the striata of schizophrenic patients and controls. Nucl. Med. Commun. 7, 599-607. (Pubitemid 16004525)
53. Dalley, J.W. and Everitt, B.J. (2009). Dopamine receptors in the learning, memory and drug reward circuitry. Semin. Cell Dev. Biol. 20, 403-410.
54. Dao-Castellana, M.H., Paillere-Martinot, M.L., Hantraye, P., Attar-Lévy, D., Rémy, P., Crouzel, C., Artiges, E., Féline, A., Syrota, A., and Martinot, J.L. (1997). Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr. Res. 23, 167-174. (Pubitemid 27106901)
55. de Haan, L., Lavalaye, J., Linszen, D., Dingemans, P.M., and Booij, J. (2000). Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am. J. Psychiatry 157, 1019-1020. (Pubitemid 30412360)
56. de Haan, L., van Bruggen, M., Lavalaye, J., Booij, J., Dingemans, P.M., and Linszen, D. (2003). Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am. J. Psychiatry 160, 303-309. (Pubitemid 41110456)
57. de Haan, L., Booij, J., Lavalaye, J., van Amelsvoort, T., and Linszen, D. (2006). Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl) 183, 500-505. (Pubitemid 41721152)
58. Demjaha, A., Egerton, A., Murray, R.M., Kapur, S., Howes, O.D., Stone, J.M., and McGuire, P.K. (2013). Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol. Psychiatry doi: pii:S0006-3223(13)00582-9.10.1016/j. biopsych.2013.06.011. Epub ahead of print.
59. Di Pietro, N.C. and Seamans, J.K. (2007). Dopamine and serotonin interactions in the prefrontal cortex: insights on antipsychotic drugs and their mechanism of action. Pharmacopsychiatry 40(Suppl 1), S27-S33.
60. Dresel, S., Tatsch, K., Dähne, I., Mager, T., Scherer, J., and Hahn, K (1998). Iodine-123-iodobenzamide SPECT assessment of dopamine D2 receptor occupancy in riperidone-treated schizophrenic patients. J. Nucl. Med. 39, 1138-1142. (Pubitemid 28326140)
61. D'Souza, D.C., Esterlis, I., Carbuto, M., Krasenics, M., Seibyl, J., Bois, F., Pittman, B., Ranganathan, M., Cosgrove, K., and Staley, J. (2012). Lower β2*-nicotinic acetylcholine receptor availability in smokers with schizophrenia. Am. J. Psychiatry 169, 326-334.
62. Elkashef, A.M., Doudet, D., Bryant, T., Cohen, R.M., Li, S.H., and Wyatt, R.J. (2000). 6-(18)F-DOPA PET study in patients with schizophrenia: positron emission tomography. Psychiatry Res. 100, 1-11.
63. Eriksen, J., Jørgensen, T.N., and Gether, U. (2010). Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J. Neurochem. 113, 27-41.
64. Eriksson, K.S., Stevens, D.R., and Haas, H.L. (2001). Serotonin excites tuberomammillary neurons by activation of Na(+)/Ca(2+)-exchange. Neuropharmacology 40, 345-351. (Pubitemid 32144712)
65. Erritzoe, D., Rasmussen, H., Kristiansen, K.T., Frokjaer, V.G., Haugbol, S., Pinborg, L., Baaré, W., Svarer, C., Madsen, J., Lublin, H., et al. (2008). Cortical and subcortical 5-HT2A receptor binding in neuroleptic-naive first-episode schizophrenic patients. Neuropsychopharmacology 33, 2435-2441.
66. Farde, L., Wiesel, F.A., Hall, H., Halldin, C., Stone-Elander, S., and Sedvall, G. (1987). No D2 receptor increase in PET study of schizophrenia. Arch. Gen. Psychiatry 44, 671-672.
67. Farde, L., Wiesel, F.A., Stone-Elander, S., Halldin, C., Nordström, A.L., Hall, H., and Sedvall, G (1990). D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride. Arch. Gen. Psychiatry 47, 213-219. (Pubitemid 20086672)
68. Ferré, S., Cortés, R., and Artigas, F. (1994). Dopaminergic regulation of the serotonergic raphe-striatal pathway: microdialysis studies in freely moving rats. J. Neurosci. 14, 4839-4846. (Pubitemid 24237906)
69. Ferreira, S.G., Teixeira, F.M., Garção, P., Agostinho, P., Ledent, C., Cortes, L., Mackie, K., and Köfalvi, A. (2012). Presynaptic CB(1) cannabinoid receptors control frontocortical serotonin and glutamate release-species differences. Neurochem. Int. 61, 219-226.
70. Ferretjans, R., Moreira, F.A., Teixeira, A.L., and Salgado, J.V. (2012). The endocannabinoid system and its role in schizophrenia: a systematic review of the literature. Rev. Bras. Psiquiatr. 34(Suppl 2), S163-S177.
71. Fink, K., Schmitz, V., Böing, C., and Göthert, M. (1995). Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via α2-heteroreceptors. Naunyn Schmiedebergs Arch. Pharmacol. 352, 394-401.
72. Folsom, T.D. and Fatemi, S.H. (2013). The involvement of Reelin in neurodevelopmental disorders. Neuropharmacology 68, 122-135.
73. Fossati, P. (2012). Neural correlates of emotion processing: from emotional to social brain. Eur. Neuropsychopharmacol. 22(Suppl 3), S487-S491.
74. Frankle, W.G., Narendran, R., Huang, Y., Hwang, D.R., Lombardo, I., Cangiano, C., Gil, R., Laruelle, M., and Abi-Dargham, A. (2005). Serotonin transporter availability in patients with schizophrenia: a positron emission tomography imaging study with [11C]DASB. Biol. Psychiatry 57, 1510-1516. (Pubitemid 40805380)
75. Frankle, W.G., Lombardo, I., Kegeles, L.S., Slifstein, M., Martin, J.H., Huang, Y., Hwang, D.R., Reich, E., Cangiano, C., Gil, R., et al. (2006). Serotonin 1A receptor availability in patients with schizophrenia and schizo-affective disorder: a positron emission tomography imaging study with [(11)C]WAY 100635. Psychopharmacology (Berl) 189, 155-164. (Pubitemid 44691538)
76. Gaebel, W. and Zielasek, J. (2009). Future classification of psychotic disorders. Eur. Arch. Psychiatry Clin. Neurosci. 259(Suppl 2), S213-S218.
77. Geaney, D.P., Ellis, P.M., Soper, N., Shepstone, B.J., and Cowen, P.J. (1992). Single photon emission tomography assessment of cerebral dopamine D2 receptor blockade in schizophrenia. Biol Psychiatry. 32, 293-295.
78. Gefvert, O., Bergström, M., Långström, B., Lundberg, T., Lindström, L., and Yates, R. (1998). Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl) 135, 119-126. (Pubitemid 28055494)
79. Giorguieff, M.F. and Le Floch, M.L. (1990). Presynaptic receptors of nicotinic and muscarinic types in the control of the spontaneous release of DA from striatal dopaminergic terminals in the rat. J. Pharmacol. Exp. Ther. 200, 535-544.
80. Girault, J.A., Spampinato, U., Glowinski, J., and Besson, M.J. (1986). In vivo release of [3H]γ-aminobutyric acid in the rat neostriatum-II. Opposing effects of D1 and D2 dopamine receptor stimulation in the dorsal caudate putamen. Neuroscience 19, 1109-1117. (Pubitemid 17217008)
81. Gjedde, A., Reith, J., and Wong, D. (1995). Dopamine receptors in schizophrenia. Lancet 346, 1302-1303.
82. Glenthoj, B.Y., Mackeprang, T., Svarer, C., Rasmussen, H., Pinborg, L.H., Friberg, L., Baaré, W., Hemmingsen, R., and Videbaek, C. (2006). Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender. Biol. Psychiatry 60, 621-629. (Pubitemid 44402367)
83. Goff, D.C. and Coyle, J.T. (2001). The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am. J. Psychiatry. 158, 1367-1377. (Pubitemid 32847232)
84. Grace, A.A. and Bunney, B.S. (1979). Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticulata inhibitory neurons. Eur. J. Pharmacol. 59, 211-218. (Pubitemid 10179608)
85. Graff-Guerrero, A., Mamo, D., Shammi, C.M., Mizrahi, R., Marcon, H., Barsoum, P., Rusjan, P., Houle, S., Wilson, A.A., and Kapur, S. (2009a). The effect of antipsychotics on the high-affinity state of D2 and D3 receptors: a positron emission tomography study With [11C]-(+)-PHNO. Arch. Gen. Psychiatry 66, 606-615.
86. Graff-Guerrero, A., Mizrahi, R., Agid, O., Marcon, H., Barsoum, P., Rusjan, P., Wilson, A.A., Zipursky, R., and Kapur, S. (2009b). The dopamine D2 receptors in high-affinity state and D3 receptors in schizophrenia: a clinical [11C]-(+)-PHNO PET study. Neuropsychopharmacology 34, 1078-1086.
87. Gray, N.S., Pilowsky, L.S., Gray, J.A., and Kerwin, R.W. (1995). Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPET. Schizophr. Res. 17, 95-107.
88. Grder, G., Landvogt, C., Vernaleken, I., Buchholz, H.G., Ondracek, J., Siessmeier, T., Htter, S., Schreckenberger, M., Stoeter, P., Hiemke, C., et al. (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31, 1027-1035.
89. Hagberg, G., Gefvert, O., Bergstr, M., Wieselgren, I.M., Lindstr, L., Wiesel, F.A., and Langstr, B. (1998). N-[11C] methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res. 82, 147-160. (Pubitemid 28341799)
90. Hahn, B., Harvey, A.N., Concheiro-Guisan, M., Huestis, M.A., Holcomb, H.H., and Gold, J.M. (2013). A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia. Biol. Psychiatry 74, 436-443.
91. Haj, M. and Rogers, B.N. (2010). Targeting 7 nicotinic acetylcholine receptors in the treatment of schizophrie. Curr. Pharm. Des. 16, 538-554.
92. Harasko-van der Meer, C., Brke, T., Wenger, S., Fischer, P., Deecke, L., and Podreka, I. (1993). Two cases of long-term dopamine D2 receptor blockade after depot neuroleptics. J. Neural Transm. Gen. Sect. 94, 217-221. (Pubitemid 24002999)
93. Hietala, J., Syvalahti, E., Vuorio, K., Nagren, K., Lehikoinen, P., Ruotsalainen, U., Rknen, V., Lehtinen, V., and Wegelius, U. (1994). Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Arch. Gen. Psychiatry 51, 116-123. (Pubitemid 24054313)
94. Hietala, J., Syvahti, E., Vuorio, K., Rknen, V., Bergman, J., Haaparanta, M., Solin, O., Kuoppami, M., Kirvel O., Ruotsalainen, U., et al. (1995). Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346, 1130-1131.
95. Hietala, J., Syvalahti, E., Vilkman, H., Vuorio, K., Rknen, V., Bergman, J., Haaparanta, M., Solin, O., Kuoppami, M., Eronen, E., et al. (1999). Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 35, 41-50. (Pubitemid 29023553)
96. Hirano, H., Day, J., and Fibiger, H.C. (1995). Serotonergic regulation of acetylcholine release in rat frontal cortex. J. Neurochem. 65, 1139-1145.
97. Hirvonen, J., van Erp, T.G., Huttunen, J., Aalto, S., Nren, K., Huttunen, M., Lnqvist, J., Kaprio, J., Cannon, T.D., and Hietala, J. (2006). Brain dopamine D1 receptors in twins discordant for schizophrenia. Am. J. Psychiatry 163, 1747-1753. (Pubitemid 44522483)
98. Howes, O.D., Montgomery, A.J., Asselin, M.C., Murray, R.M., Valli, I., Tabraham, P., Bramon-Bosch, E., Valmaggia, L., Johns, L., Broome, M., et al. (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 66, 13-20.
99. Hsiao, M.C., Lin, K.J., Liu, C.Y., Tzen, K.Y., and Yen, T.C. (2003). Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1. Schizophr. Res. 65, 39-46.
100. Ibanez-Casas, I. and Cervilla, J.A. (2012). Neuropsychological research in delusional disorder: a comprehensive review. Psychopathology 45, 78-95.
101. Ito, C. (2004). The role of the central histaminergic system on schizophrenia. Drug News Perspect. 17, 383-387. (Pubitemid 39295642)
102. Itokawa, M., Arinami, T., and Toru, M. (2010). Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: Ser311Cys polymorphisms of the dopamine D2-receptor gene and schizophrenia. J. Pharmacol. Sci. 114, 1-5.
103. Iwabuchi, K., Ito, C., Tashiro, M., Kato, M., Kano, M., Itoh, M., Iwata, R., Matsuoka, H., Sato, M., and Yanai, K. (2005). Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur. Neuropsychopharmacol. 15, 185-191. (Pubitemid 40193424)
104. Jablensky, A., Sartorius, N., Ernberg, G., Anker, M., Korten, A., Cooper, J.E., Day, R., and Bertelsen, A. (1992). Schizophrenia: manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol. Med. Monogr. Suppl. 20, 1-97.
105. Jenkins, G. and Rricht, F. (2007). From cenesthesias to cenesthopathic schizophrenia: a historical and phenomenological review. Psychopathology 40, 361-368. (Pubitemid 47254523)
106. Jones, H.M., Travis, M.J., Mulligan, R., Visvikis, D., Gacinovic, S., Ell, P.J., Kerwin, R.W., and Pilowsky, L.S. (2000). In vivo serotonin 5-HT(2A) receptor occupancy and quetiapine. Am. J. Psychiatry 157, 148.
107. Jones, H.M., Travis, M.J., Mulligan, R., Bressan, R.A., Visvikis, D., Gacinovic, S., Ell, P.J., and Pilowsky, L.S. (2001). In vivo 5-HT2A receptor blockade by quetiapine: an R91150 single photon emission tomography study. Psychopharmacology (Berl) 157, 60-66. (Pubitemid 32758960)
108. Karlsson, P., Farde, L., Halldin, C., and Sedvall, G. (2002). PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am. J. Psychiatry 159, 761-767. (Pubitemid 34465049)
109. Kasper, S., Tauscher, J., Kferle, B., Barnas, C., Hesselmann, B., Asenbaum, S., Podreka, I., and Brke, T. (1998). Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol-a 123I-IBZM SPECT study. Psychopharmacology (Berl) 136, 367-373. (Pubitemid 28189666)
110. Kim, J.H., Son, Y.D., Kim, H.K., Lee, S.Y., Cho, S.E., Kim, Y.B., and Cho, Z.H. (2011). Antipsychotic-associated mental side effects and their relationship to dopamine D2 receptor occupancy in striatal subdivisions: a high-resolution PET study with [11C] raclopride. J. Clin. Psychopharmacol. 31, 507-511.
111. Knable, M.B. and Weinberger, D.R. (1997). Dopamine, the prefrontal cortex and schizophrenia. Psychopharmacology 11, 123-131. (Pubitemid 27252643)
112. Konradi, C. and Heckers, S. (2003). Molecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment. Pharmacol. Ther. 97, 153-179. (Pubitemid 36138820)
113. Kosaka, J., Takahashi, H., Ito, H., Takano, A., Fujimura, Y., Matsumoto, R., Nozaki, S., Yasuno, F., Okubo, Y., Kishimoto, T., et al. (2010). Decreased binding of [11C]NNC112 and [11C] SCH23390 in patients with chronic schizophrenia. Life Sci. 86, 814-818.
114. Kferle, B., Brke, T., Topitz-Schratzberger, A., Tauscher, J., Gsler, R., Vesely, C., Asenbaum, S., Podreka, I., and Kasper, S. (1996). Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone Psychiatry Res. 68, 23-30. (Pubitemid 27062648)
115. Kferle, B., Tauscher, J., Asenbaum, S., Vesely, C., Podreka, I., Brke, T., and Kasper, S. (1997). IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 133, 323-328. (Pubitemid 27462804)
116. Kuhar, M.J., Couceyro, P.R., and Lambert, P.D. (1998). Catecholamines. Basic Neurochemistry-Molecular, Cellular and Medical Aspects. 6th ed. G.I. Siegel, B.W. Agranoff, R.W. Albers, S.K Fisher, and M.D. Whler, eds. (Baltimore: Lippincott, Williams & Wilkins), pp. 243-261.
117. Kumakura, Y., Cumming, P., Vernaleken, I., Buchholz, H.G., Siessmeier, T., Heinz, A., Kienast, T., Bartenstein, P., and Grder, G. (2007). Elevated [18F]fluorodopamine turnover in brain of patients with schizophrenia: an [18F]fluorodopa/positron emission tomography study. J. Neurosci. 27, 8080-8087. (Pubitemid 47173328)
118. Kstler, U., Hohdorf, K., Regenthal, R., Seese, A., and Gertz, H.J. (2000). Diminution of hand writing area and D2-dopamine receptor blockade. Results from treatment with typical and atypical neuroleptics. Nervenarzt 71, 373-379.
119. Laakso, A., Vilkman, H., Alakare, B., Haaparanta, M., Bergman, J., Solin, O., Peurasaari, J., Rknen, V., Syvahti, E., and Hietala, J. (2000). Striatal dopamine transporter binding in neuroleptic-naive patients with schizophrenia studied with positron emission tomography. Am. J. Psychiatry 157, 269-271. (Pubitemid 30080910)
120. Laakso, A., Bergman, J., Haaparanta, M., Vilkman, H., Solin, O., Syvahti, E., and Hietala, J. (2001). Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr. Res. 52, 115-120. (Pubitemid 32947054)
121. la Fougere, C., Krause, J., Krause, K.H., Josef Gildehaus, F., Hacker, M., Koch, W., Hahn, K., Tatsch, K., and Dresel, S. (2006). Value of 99mTc-TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder. Nucl. Med. Commun. 27, 733-737. (Pubitemid 44213031)
122. Laguerre, A., Leboyer, M., and Schhoff, F. (2008). The schizotypal personality disorder: historical origins and current status. Encephale 34, 17-22. (Pubitemid 351621970)
123. Lahti, A.C., Weiler, M.A., Tamara Michaelidis, B.A., Parwani, A., and Tamminga, C.A. (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25, 455-467. (Pubitemid 32830950)
124. Lang, U.E., Puls, I., Mler, D.J., Strutz-Seebohm, N., and Gallinat, J. (2007). Molecular mechanisms of schizophrenia. Cell. Physiol. Biochem. 20, 687-702. (Pubitemid 350059714)
125. Lanteri, C., Herndez Vallejo, S.J., Salomon, L., Doucet, E.L., Godeheu, G., Torrens, Y., Houades, V., and Tassin, J.P. (2009). Inhibition of monoamine oxidases desensitizes 5-HT1A autoreceptors and allows nicotine to induce a neurochemical and behavioral sensitization. J. Neurosci. 29, 987-997.
126. Laruelle, M. (1998). Imaging dopamine transmission in schizophrenia: a review and meta-analysis. Q. J. Nucl. Med. 42, 211-221. (Pubitemid 28529874)
127. Laruelle, M. and Abi-Dargham, A. (1999). Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies. J. Psychopharmacol. 13, 358-371. (Pubitemid 30055180)
128. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., D'Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., et al. (1996). Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. USA 93, 9235-9240.
129. Laruelle, M., Abi-Dargham, A., Gil, R., Kegeles, L., and Innis, R. (1999). Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol. Psychiatry 46, 56-72. (Pubitemid 29296818)
130. Laruelle, M., Abi-Dargham, A., van Dyck, C., Gil, R., D'Souza, D.C., Krystal, J., Seibyl, J., Baldwin, R., and Innis, R. (2000). Dopamine and
131. Lasser, K., Boyd, J.W., Woolhandler, S., Himmelstein, D.U., McCormick, D., and Bor, D.H. (2000). Smoking and mental illness: a population-based prevalence study. J. Am. Med. Assoc. 284, 2606-2610.
132. Lavalaye, J., Linszen, D.H., Booij, J., Dingemans, P.M., Reneman, L., Habraken, J.B., Gersons, B.P., and van Royen, E.A. (2001a). Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT. Schizophr. Res. 47, 59-67. (Pubitemid 32121771)
133. Lavalaye, J., Booij, J., Linszen, D.H., Reneman, L., and van Royen, E.A. (2001b). Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia A[123I]-IDEX SPECT study. Psychopharmacology (Berl) 156, 53-57. (Pubitemid 32646324)
134. Lehmann, J. and Langer, S.Z. (1983). The striatal cholinergic interneuron: synaptic target of dopaminergic terminals Neuroscience 10, 1105-1120. (Pubitemid 14178563)
135. Lerond, J., Lothe, A., Ryvlin, P., Bouvard, S., d'Amato, T., Ciumas, C., Daly, J., Poulet, E., and Saoud, M. (2013). Effects of aripiprazole, risperidone, and olanzapine on 5-HT1A receptors in patients with schizophrenia. J. Clin. Psychopharmacol. 33, 84-89.
136. Lewis, R., Kapur, S., Jones, C., DaSilva, J., DaSilva, J., Brown, G.M., Wilson, A.A., Houle, S., and Zipursky, R.B. (1999). Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F] setoperone in neuroleptic-naive patients and normal subjects. Am. J. Psychiatry 156, 72-78. (Pubitemid 29034882)
137. Lindstrom, L.H., Gefvert, O., Hagberg, G., Lundberg, T., Bergstr, M., Hartvig, P., and Langstr, B. (1999). Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(-11C) DOPA and PET. Biol. Psychiatry 46, 681-688. (Pubitemid 29401864)
138. Lipska, B.K. (2004). Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J. Psychiatry Neurosci. 29, 282-286. (Pubitemid 39179574)
139. Lipska, B.K. and Weinberger, D.R. (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23, 223-239. (Pubitemid 30609657)
140. Lundberg, T., Lindstr, L.H., Hartvig, P., Eckernas, S.A., Ekblom, B., Lundqvist, H., Fasth, K.J., Gullberg, P., and Langstr, B. (1989). Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers. Psychopharmacology (Berl) 99, 8-12. (Pubitemid 19201706)
141. Luparini, M.R., Garrone, B., Pazzagli, M., Pinza, M., and Pepeu, G. (2004). A cortical GABA-5HT interaction in the mechanism of action of the antidepressant trazodone. Prog. Neuropsychopharmacol. Biol. Psychiatry. 28, 1117-1127. (Pubitemid 40017628)
142. Malhi, G.S., Green, M., Fagiolini, A., Peselow, E.D., and Kumari, V. (2008). Schizoaffective disorder: diagnostic issues and future recommendations. Bipolar Disord. 10, 215-230.
143. Mamo, D., Graff, A., Mizrahi, R., Shammi, C.M., Romeyer, F., and Kapur, S. (2007). Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am. J. Psychiatry 164, 1411-1417. (Pubitemid 47461142)
144. Mane, A., Gallego, J., Lome, F., Mateos, J.J., Fernandez-Egea, E., Horga, G., Cot, A., Pavia, J., Bernardo, M., and Parellada, E. (2011). A 4-year dopamine transporter (DAT) imaging study in neuroleptic-naive first episode schizophrenia patients. Psychiatry Res. 194, 79-84.
145. Marchi, M., Fontana, G., Paudice, P., and Raiteri, M. (1988). The activation of phosphatidylinositol turnover is not directly involved in the modulation of neurotransmitter release mediated by presynaptic muscarinic receptors. Neurochem. Res. 13, 903-907.
146. Martinot, J.L., Huret, J.D., Peron-Magnan, P., Mazoyer, B.M., Baron, J.C., Caillard, V., Syrota, A., and Loo, H. (1989). Striatal D2 dopaminergic receptor status ascertained in vivo by positron emission tomography and 76Br-bromospiperone in untreated schizophrenics. Psychiatry Res. 29, 357-358. (Pubitemid 19265391)
147. Martinot, J.L., Paillere-Martinot, M.L., Loc'h, C., Hardy, P., Poirier, M.F., Mazoyer, B., Beaufils, B., Mazie, B., Allilaire, J.F., and Syrota, A. (1991). The estimated density of D2 striatal receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br. J. Psychiatry 158, 346-350.
148. Martinot, J.L., Paillere-Martinot, M.L., Loc'h, C., Lecrubier, Y., Dao-Castellana, M.H., Aubin, F., Allilaire, J.F., Mazoyer, B., Mazie, B., and Syrota, A. (1994). Central D2 receptors and negative symptoms of schizophrenia. Br. J. Psychiatry 164, 27-34.
149. Mateos, J.J., Lomena, F., Parellada, E., Font, M., Fernandez, E., Pavia, J., Prats, A., Pons, F., and Bernardo, M. (2005). Decreased striatal dopamine transporter binding assessed with [123I] FP-CIT in first-episode schizophrenic patients with and without short-term antipsychotic-induced parkinsonism. Psychopharmacology (Berl) 181, 401-406. (Pubitemid 41492210)
150. Mateos, J.J., Lomena, F., Parellada, E., Font, M., Ferndez, E., Pavia, J., Prats, A., and Bernardo, M. (2006). Striatal dopamine transporter density decrease in first episode schizophrenic patients treated with risperidone. Rev. Esp. Med. Nucl. 25, 159-165. (Pubitemid 43967133)
151. Mateos, J.J., Lome, F., Parellada, E., Mireia, F., Fernandez-Egea, E., Pavia, J., Prats, A., Pons, F., and Bernardo, M. (2007). Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait. Psychopharmacology (Berl) 191, 805-811. (Pubitemid 46355894)
152. Maura, G., Ricchetti, A., and Raiteri, M. (1986). Serotonin inhibits the depolarization-evoked release of endogenous glutamate from rat cerebellar nerve endings. Neurosci. Lett. 67, 218-222. (Pubitemid 16034551)
153. McGowan, S., Lawrence, A.D., Sales, T., Quested, D., and Grasby, P. (2004). Presynaptic dopaminergic dysfunction in schizophrenia: a positron emission tomographic [18F] fluorodopa study. Arch. Gen. Psychiatry. 61, 134-142. (Pubitemid 38146547)
154. Meisenzahl, E.M., Dresel, S., Frodl, T., Schmitt, G.J., Preuss, U.W., Rossmler, B., Tatsch, K., Mager, T., Hahn, K., and Mler, H.J. (2000). D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J. Psychopharmacol. 14, 364-370. (Pubitemid 32059781)
155. Meisenzahl, E.M., Schmitt, G., Grder, G., Dresel, S., Frodl, T., la Fouge, C., Scheuerecker, J., Schwarz, M., Boerner, R., Stauss, J., et al. (2008). Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 41, 169-175.
156. Meltzer, H.Y. (2012). Serotonergic mechanisms as targets for existing and novel antipsychotics. Handb Exp Pharmacol. 212, 87-124.
157. Meneses, A. and Liy-Salmeron, G. (2012). Serotonin and emotion, learning and memory. Rev. Neurosci. 23, 543-553.
158. Meyer-Lindenberg, A., Miletich, R.S., Kohn, P.D., Esposito, G., Carson, R.E., Quarantelli, M., Weinberger, D.R., and Berman, K.F. (2012). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5, 267-371.
159. Miranda, M. and Sorkin, A. (2007). Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol. Interv. 7, 157-167. (Pubitemid 47026726)
160. Miyamoto, S., Duncan, G.E., Marx, C.E., and Lieberman, J.A. (2005). Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol. Psychiatry 10, 79-104. (Pubitemid 40139590)
161. Muller, P. and Seeman, P. (1979). Presynaptic subsensitivity as a possible basis for sensitization by long-term dopamine mimetics. Eur. J. Pharmacol. 55, 149-157. (Pubitemid 9215639)
162. Napier, T.C. and Istre, E.D. (2008). Methamphetamine-induced sensitization includes a functional upregulation of ventral pallidal 5-HT2A/2C receptors. Synapse 62, 14-21. (Pubitemid 350156139)
163. Ngan, E.T., Yatham, L.N., Ruth, T.J., and Liddle, P.F. (2000). Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: a PET study using [(18)F] setoperone. Am. J. Psychiatry 157, 1016-1018. (Pubitemid 30412359)
164. Nikolaus, S., Beu, M., Wirrwar, A., Vosberg, H., Mler, H.W., and Larisch, R. (2004). The contribution of small animal positron emission tomography to the neurosciences-a critical evaluation. Rev. Neurosci. 15, 131-156. (Pubitemid 38858894)
165. Nikolaus, S., Antke, C., Kley, K., Poeppel, T.D., Hautzel, H., Schmidt, D., and Mler, H.W. (2007a). Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev. Neurosci. 18, 439-472. (Pubitemid 351184054)
166. Nikolaus, S., Larisch, R., Beu, M., Antke, C., Kley, K., Forutan, F., Wirrwar, A., and Mler, H.W. (2007b). Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev. Neurosci. 18, 473-505.
167. Nikolaus, S., Antke, C., and Mler, H.W. (2009). In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav. Brain Res. 204, 32-66.
168. Nikolaus, S., Beu, M., Antke, C., and Mler, H.W. (2010). Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders-results from in vivo imaging studies. Rev. Neurosci. 21, 119-139.
169. Nikolaus, S., Hautzel, H., Heinzel, A., and Mler, H.W. (2012). Key players in major and bipolar depression-a retrospective analysis of in vivo imaging studies. Behav. Brain Res. 232, 358-390.
170. Nikolaus, S., de Souza Silva, M.A., Hautzel, H., Huston, J.P., and Mler, H.W. (2013). The neurotachykinin NK1 receptor-a novel target for diagnostics and therapy. Curr. Mol. Imaging 2, 130-147.
171. Nordstr, A.L., Farde, L., Pauli, S., Litton, J.E., and Halldin, C. (1992). PET analysis of central [11C]raclopride binding in healthy young adults and schizophrenic patients-reliability and age effects. Human Psychopharmacol. 7, 157-165.
172. Nordstr, A.L., Farde, L., Nyberg, S., Karlsson, P., Halldin, C., and Sedvall, G. (1995a). D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry 152, 1444-1449.
173. Nordstr, A.L., Farde, L., Eriksson, L., and Halldin, C. (1995b). No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone. Psychiatry Res. 61, 67-83.
174. Nozaki, S., Kato, M., Takano, H., Ito, H., Takahashi, H., Arakawa, R., Okumura, M., Fujimura, Y., Matsumoto, R., Ota, M., et al. (2009). Regional dopamine synthesis in patients with schizophrenia using L-[-11C]DOPA PET. Schizophr. Res. 108, 78-84.
175. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (1997). Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385, 634-636.
176. Okubo, Y., Suhara, T., Suzuki, K., Kobayashi, K., Inoue, O., Terasaki, O., Someya, Y., Sassa, T., Sudo, Y., Matsushima, E., et al. (2000). Serotonin 5-HT2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci. 66, 2455-2564.
177. Palacios, J.M., Camps, M., Cort, R., and Probst, A. (1988). Mapping dopamine receptors in the human brain. J. Neural Transm. Suppl. 27, 227-235.
178. Paquet, F., Soucy, J.P., Stip, E., Lesque, M., Elie, A., and Bard, M.A. (2004). Comparison between olanzapine and haloperidol on procedural learning and the relationship with striatal D2 receptor occupancy in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 16, 47-56. (Pubitemid 38233363)
179. Pearlson, G.D., Tune, L.E., Wong, D.F., Aylward, E.H., Barta, P.E., Powers, R.E., Tien, A.Y., Chase, G.A., Harris, G.J., and Rabins, P.V. (1993). Quantitative D2 dopamine receptor PET and structural MRI changes in late-onset schizophrenia. Schizophr. Bull. 19, 783-795.
180. Pearlson, G.D., Wong, D.F., Tune, L.E., Ross, C.A., Chase, G.A., Links, J.M., Dannals, R.F., Wilson, A.A., Ravert, H.T., Wagner, H.N., Jr., et al. (1995). In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch. Gen. Psychiatry 52, 471-477.
181. Pedro, B.M., Pilowsky, L.S., Costa, D.C., Hemsley, D.R., Ell, P.J., Verhoeff, N.P., Kerwin, R.W., and Gray, N.S. (1994). Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia. Psychol. Med. 24, 423-429. (Pubitemid 24158855)
182. Pehek, E.A. and Yamamoto, B.K. (1994). Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J. Neurochem. 63, 2118-2124. (Pubitemid 24369986)
183. Pez, V. Catafau, A.M., Corripio, I., Mart, J.C., and Alvarez, E. (2003). Preliminary evidence of striatal D2 receptor density as a possible biological marker of prognosis in naive schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 767-770. (Pubitemid 36966757)
184. Pickar, D., Su, T.P., Weinberger, D.R., Coppola, R., Malhotra, A.K., Knable, M.B., Lee, K.S., Gorey, J., Bartko, J.J., Breier, A., et al. (1996). Individual variation in D2 dopamine receptor occupancy in clozapine-treated patients. Am. J. Psychiatry 153, 1571-1578. (Pubitemid 26406167)
185. Pilowsky, L.S., Costa, D.C., Ell, P.J., Murray, R.M., Verhoeff, N.P., and Kerwin, R.W. (1992). Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 340, 199-202.
186. Pilowsky, L.S., Costa, D.C., Ell, P.J., Murray, R.M., Verhoeff, N.P., and Kerwin, R.W. (1993). Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. Psychol. Med. 23, 791-797. (Pubitemid 23268097)
187. Pilowsky, L.S., Costa, D.C., Ell, P.J., Verhoeff, N.P., Murray, R.M., and Kerwin, R.W. (1994). D2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients: an 123I-IBZM single photon emission computerised tomography study. Br. J. Psychiatry 164, 16-26.
188. Pilowsky, L.S., Bressan, R.A., Stone, J.M., Erlandsson, K., Mulligan, R.S., Krystal, J.H., and Ell, P.J. (2006). First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol. Psychiatry 11, 118-119. (Pubitemid 43164609)
189. Pogarell, O., Koch, W., Karch, S., Dehning, S., Mler, N., Tatsch, K., Poepperl, G., and Mler, H.J. (2012). Dopaminergic neurotransmission in patients with schizophrenia in relation to positive and negative symptoms. Pharmacopsychiatry 45(Suppl 1), S36-S41.
190. Rada, P.V., Mark, G.P., and Hoebel, B.G. (1993). In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats: I. Inhibition by serotonin. Brain Res. 619, 98-104. (Pubitemid 23214310)
191. Raedler, T.J., Knable, M.B., Lafargue, T., Urbina, R.A., Egan, M.F., Pickar, D., and Weinberger, D.R. (1999). In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. 90, 81-90. (Pubitemid 29256138)
192. Raedler, T.J., Knable, M.B., Jones, D.W., Urbina, R.A., Gorey, J.G., Lee, K.S., Egan, M.F., Coppola, R., and Weinberger, D.R. (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am. J. Psychiatry 160, 118-127. (Pubitemid 36042435)
193. Reeves, S., Brown, R., Howard, R., and Grasby, P. (2009). Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease. Neurology 72, 528-534.
194. Redpath, H.L., Lawrie, S.M., Sprooten, E., Whalley, H.C., McIntosh, A.M., and Hall, J. (2013). Progress in imaging the effects of psychosis susceptibility gene variants. Expert Rev Neurother. 13, 37-47.
195. Reimold, M., Solbach, C., Noda, S., Schaefer, J.E., Bartels, M., Beneke, M., Machulla, H.J., Bares, R., Glaser, T., and Wormstall, H. (2007). Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 190, 241-249. (Pubitemid 46011184)
196. Reith, J., Benkelfat, C., Sherwin, A., Yasuhara, Y., Kuwabara, H., Andermann, F., Bachneff, S., Cumming, P., Diksic, M., Dyve, S.E., et al. (1994). Elevated DOPA decarboxylase activity in living brain of patients with psychosis. Proc. Natl. Acad. Sci. USA 91, 11651-11654. (Pubitemid 24356402)
197. Rendu, F., Peoc'h, K., Berlin, I., Thomas, D., and Launay, J.M. (2011). Smoking related diseases: the central role of monoamine oxidase. Int. J. Environ. Res. Public Health 8, 136-147.
198. Ring, H.A., Trimble, M.R., Costa, D.C., Moriarty, J., Verhoeff, N.P.L.G., and Ell, P.J. (1994). Striatal dopamine receptor binding in epileptic psychoses. Biol. Psychiatry 35, 375-380. (Pubitemid 24118465)
199. Rollema, H., Coe, J.W., Chambers, L.K., Hurst, R.S., Stahl, S.M., and Williams, K.E. (2007). Rationale, pharmacology and clinical efficacy of partial agonists of 42 nACh receptors for smoking cessation. Trends Pharmacol. Sci. 28, 316-325. (Pubitemid 47016686)
200. Safont, G., Corripio, I., Escart M.J., Portella, M.J., Pez, V., Ferrer, M., Camacho, V., Sauras, R.B., Alonso, A., Grasa, E.M., et al. (2011). Cannabis use and striatal D2 receptor density in untreated first-episode psychosis: an in vivo SPECT study. Schizophr. Res. 129, 169-171.
201. Scherer, J., Tatsch, K., Schwarz, J., Oertel, W., Kirsch, M.C., and Albus, M. (1994a). Striatal D2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biol. Psychiatry 36, 627-629.
202. Scherer, J., Tatsch, K., Schwarz, J., Oertel, W.H., Konjarczyk, M., and Albus, M. (1994b). D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr. Scand. 90, 266-268. (Pubitemid 24303594)
203. Schmitt, G.J., Meisenzahl, E.M., Dresel, S., Tatsch, K., Rossmler, B., Frodl, T., Preuss, U.W., Hahn, K., and Mler, H.J. (2002). Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. J. Psychopharmacol. 16, 200-206. (Pubitemid 34983073)
204. Schmitt, G.J., Meisenzahl, E.M., Frodl, T., La Fouge, C., Hahn, K., Mler, H.J., and Dresel, S. (2005). The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: evaluation by the new SPECT-ligand[99mTc]TRODAT-1. J. Psychopharmacol. 19, 488-493. (Pubitemid 41392303)
205. Schmitt, G.J., Frodl, T., Dresel, S., La Fouge, C., Bottlender, R., Koutsouleris, N., Hahn, K., Mler, H.J., and Meisenzahl, E.M. (2006). Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur. Arch. Psychiatry Clin. Neurosci. 256, 115-121.
206. Schmitt, G.J., La Fouge, C., Dresel, S., Frodl, T., Hahn, K., Mler, H.J., and Meisenzahl, E.M. (2008). Dual-isotope SPECT imaging of striatal dopamine: first episode, drug nae schizophrenic patients. Schizophr. Res. 101, 133-411.
207. Schmitt, G.J., Meisenzahl, E.M., Frodl, T., La Fouge, C., Hahn, K., Mler, H.J., and Dresel, S. (2009). Increase of striatal dopamine transmission in first episode drug-naive schizophrenic patients as demonstrated by [(123)I]IBZM SPECT. Psychiatry Res. 173, 183-189.
208. Schulz, D. and Vaska, P. (2011). Integrating PET with behavioral neuroscience using RatCAP tomography. Rev. Neurosci. 22, 647-655.
209. Schwarz, J., Scherer, J., Trenkwalder, C., Mozley, P.D., and Tatsch, K. (1998). Reduced striatal dopaminergic innervation shown by IPT and SPECT in patients under neuroleptic treatment: need for levodopa therapy Psychiatry Res. 83, 23-28. (Pubitemid 28384468)
210. Seeman, P. and Lee, T. (1975). Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. Science 188, 1217-1219.
211. Shotbolt, P., Stokes, P.R., Owens, S.F., Toulopoulou, T., Picchioni, M.M., Bose, S.K., Murray, R.M., and Howes, O.D. (2011). Striatal dopamine synthesis capacity in twins discordant for schizophrenia. Psychol. Med. 41, 2331-2338.
212. Sjoholm, H., Bratlid, T., and Sundsfjord, J. (2004). 123I-CIT SPECT demonstrates increased presynaptic dopamine transporter binding sites in basal ganglia in vivo in schizophrenia. Psychopharmacology (Berl) 173, 27-31. (Pubitemid 38591143)
213. Smith, M., Wolf, A.P., Brodie, J.D., Arnett, C.D., Barouche, F., Shiue, C.Y., Fowler, J.S., Russell, J.A., MacGregor, R.R., Wolkin, A., et al. (1988). Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol. Psychiatry 23, 653-663. (Pubitemid 18086644)
214. Son, L.Z., Yanai, K., Mobarakeh, J.I., Kuramasu, A., Li, Z.Y., Sakurai, E., Hashimoto, Y., Watanabe, T., and Watanabe, T. (2001). Histamine H1 receptor-mediated inhibition of potassium-evoked release of 5-hydroxytryptamine from mouse forebrains. Behav. Brain Res. 124, 113-120. (Pubitemid 32964628)
215. Sprouse, J.S. and Aghajanian, G.K. (1987). Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists. Synapse 1, 3-9. (Pubitemid 17114243)
216. Steiner, J.A., Carneiro, A.M., and Blakely, R.D. (2008). Going with the flow: trafficking-dependent and-independent regulation of serotonin transport. Traffic 9, 1393-1402.
217. Suhara, T., Okubo, Y., Yasuno, F., Sudo, Y., Inoue, M., Ichimiya, T., Nakashima, Y., Nakayama, K., Tanada, S., Suzuki, K., et al. (2002). Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 59, 25-30. (Pubitemid 34044401)
218. Suridjan, I., Rusjan, P., Addington, J., Wilson, A.A., Houle, S., and Mizrahi, R. (2013). Dopamine D2 and D3 binding in people at clinical high risk for schizophrenia, antipsychotic-naive patients and healthy controls while performing a cognitive task. J. Psychiatry Neurosci. 38, 98-106.
219. Suzuki, M. (2003). Schizophreniform disorder. Ryoikibetsu Shokogun Shirizu 38, 60-63.
220. Suzuki, A. (2012). Emotional functions of the insula. Brain Nerve 64, 1103-1112.
221. Talvik, M., Nordstr, A.L., Olsson, H., Halldin, C., and Farde, L. (2003). Decreased thalamic D2/D3 receptor binding in drug-naive patients with schizophrenia: a PET study with [11C] FLB 457. Int. J. Neuropsychopharmacol. 6, 361-370. (Pubitemid 38146254)
222. Talvik, M., Nordstr, A.L., Okubo, Y., Olsson, H., Borg, J., Halldin, C., and Farde, L. (2006). Dopamine D2 receptor binding in drug-nae patients with schizophrenia examined with raclopride-C11 and positron emission tomography. Psychiatry Res. 148, 165-173. (Pubitemid 44750590)
223. Tauscher, J., Kferle, B., Asenbaum, S., Brke, T., and Kasper, S. (1997). Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology (Berl) 133, 102-105. (Pubitemid 27395827)
224. Tauscher, J., Kferle, B., Asenbaum, S., Fischer, P., Pezawas, L., Barnas, C., Tauscher-Wisniewski, S., Brke, T., and Kasper, S. (1999). In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 141, 175-181. (Pubitemid 29200169)
225. Tauscher, J., Kapur, S., Verhoeff, N.P., Hussey, D.F., Daskalakis, Z.J., Tauscher-Wisniewski, S., Wilson, A.A., Houle, S., Kasper, S., and Zipursky, R.B. (2002). Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635. Arch. Gen. Psychiatry 59, 514-520. (Pubitemid 34602933)
226. Taylor, S.F., Koeppe, R.A., Tandon, R., Zubieta, J.K., and Frey, K.A. (2000). In vivo measurement of the vesicular monoamine transporter in schizophrenia. Neuropsychopharmacology 23, 667-675.
227. Tibbo, P., Silverstone, P.H., McEwan, A.J., Scott, J., Joshua, A., and Golberg, K. (1997). A single photon emission computed tomography scan study of striatal dopamine D2 receptor binding with 123I-epidepride in patients with schizophrenia and controls. J. Psychiatry Neurosci. 22, 39-45.
228. Toda, M. and Abi-Dargham, A. (2007). Dopamine hypothesis of schizophrenia: making sense of it all. Curr. Psychiatry Rep. 9, 329-336. (Pubitemid 47490006)
229. Travis, M.J., Busatto, G.F., Pilowsky, L.S., Mulligan, R., Acton, P.D., Gacinovic, S., Mertens, J., Terrie, D., Costa, D.C., Ell, P.J., et al. (1998). 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine. A SPET study using the novel 5-HT2A ligand 123I-5-I-R-91150. Br. J. Psychiatry 173, 236-421.
230. Trichard, C., Paille-Martinot, M.L., Attar-Levy, D., Blin, J., Feline, A., and Martinot, J.L. (1998). No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr. Res. 31, 13-17. (Pubitemid 28234340)
231. Tune, L.E., Wong, D.F., Pearlson, G., Strauss, M., Young, T., Shaya, E.K., Dannals, R.F., Wilson, A.A., Ravert, H.T., Sapp, J., et al. (1993). Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res. 49, 219-237.
232. Tune, L., Barta, P., Wong, D., Powers, R.E., Pearlson, G., Tien, A.Y., and Wagner, H.N. (1996). Striatal dopamine D2 receptor quantification and superior temporal gyrus: volume determination in 14 chronic schizophrenic subjects. Psychiatry Res. 67, 155-158. (Pubitemid 26299340)
233. Tuppurainen, H., Kuikka, J., Viinami, H., Husso-Saastamoinen, M., Bergstr, K., and Tiihonen, J. (2003). Extrastriatal dopamine D 2/3 receptor density and distribution in drug-naive schizophrenic patients. Mol. Psychiatry 8, 453-455. (Pubitemid 36609670)
234. Tuppurainen, H., Kuikka, J.T., Laakso, M.P., Viinami, H., Husso, M., and Tiihonen, J. (2006). Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 256, 382-387. (Pubitemid 44393006)
235. Uchida, H., Graff-Guerrero, A., Mulsant, B.H., Pollock, B.G., and Mamo, D.C. (2009). Long-term stability of measuring D(2) receptors in schizophrenia patients treated with antipsychotics. Schizophr. Res. 109, 130-133.
236. Vallabhajosula, S., Hirschowitz, J., and Machac, J. (1997). Effect of haloperidol dose on iodine-123-IBZM brain SPECT imaging in schizophrenic patients. J. Nucl. Med. 38, 203-207. (Pubitemid 27061594)
237. Valli, I., Howes, O., Tyrer, P., McGuire, P., and Grasby, P.M. (2008). Longitudinal PET imaging in a patient with schizophrenia did not show marked changes in dopaminergic function with relapse of psychosis. Am. J. Psychiatry 165, 1613-1614.
238. Verhoeff, N.P., Meyer, J.H., Kecojevic, A., Hussey, D., Lewis, R., Tauscher, J., Zipursky, R.B., and Kapur, S. (2000). A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res. 99, 123-135.
239. Vernaleken, I., Siessmeier, T., Buchholz, H.G., Htter, S., Hiemke, C., Stoeter, P., Rch, F., Bartenstein, P., and Grder, G. (2004). High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int. J. Neuropsychopharmacol. 7, 421-430. (Pubitemid 39648072)
240. Volk, S., Maul, F.D., H, G., Schreiner, M., Weppner, M., Holzmann, T., and Pflug, B. (1994). Dopamine D2 receptor occupancy measured by single photon emission computed tomography with 123I-iodobenzamide in chronic schizophrenia. Psychiatry Res. 55, 111-118.
241. Walther, S. and Strik, W. (2012). Motor symptoms and schizophrenia. Neuropsychobiology 66, 77-92.
242. Wong, D.F., Wagner, H.N. Jr., Tune, L.E., Dannals, R.F., Pearlson, G.D., Links, J.M., Tamminga, C.A., Broussolle, E.P., Ravert, H.T., Wilson, A.A., et al. (1986). Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science 234, 1558-1563. (Pubitemid 17125279)
243. Wong, D.F., Pearlson, G.D., Tune, L.E., Young, L.T., Meltzer, C.C., Dannals, R.F., Ravert, H.T., Reith, J., Kuhar, M.J., and Gjedde, A. (1997). Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J. Cereb. Blood Flow Metab. 17, 331-342. (Pubitemid 27161376)
244. Wong, D.F., Kuwabara, H., Horti, A.G., Raymont, V., Brasic, J., Guevara, M., Ye, W., Dannals, R.F., Ravert, H.T., Nandi, A., et al. (2010). Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR. Neuroimage 52, 1505-1513.
245. World Health Organization. 2010. The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research (Geneva, Switzerland: WHO).
246. Xiberas, X., Martinot, J.L., Mallet, L., Artiges, E., Loc'H, C., Mazie, B., and Paille-Martinot, M.L. (2001). Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br. J. Psychiatry 179, 503-508. (Pubitemid 34031674)
247. Yamamoto, B.K. and Davy, S. (1992). Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem. 58, 1736-1742.
248. Yang, Y.K., Chiu, N.T., Chen, C.C., Chen, M., Yeh, T.L., and Lee, I.H. (2003). Correlation between fine motor activity and striatal dopamine D2 receptor density in patients with schizophrenia and healthy controls. Psychiatry Res. 123, 191-197. (Pubitemid 36962962)
249. Yang, Y.K., Yu, L., Yeh, T.L., Chiu, N.T., Chen, P.S., and Lee, I.H. (2004). Associated alterations of striatal dopamine D2/D3 receptor and transporter binding in drug-naive patients with schizophrenia: a dual-isotope SPECT study. Am. J. Psychiatry 161, 1496-1498. (Pubitemid 38989108)
250. Yanovsky, Y., Li, S., Klyuch, B.P., Yao, Q., Blandina, P., Passani, M.B., Lin, J.S., Haas, H.L., and Sergeeva, O.A. (2011). l-dopa activates histaminergic neurons. J. Physiol. 589, 1349-1466.
251. Yasuno, F., Suhara, T., Okubo, Y., Sudo, Y., Inoue, M., Ichimiya, T., Takano, A., Nakayama, K., Halldin, C., and Farde, L. (2004a). Low dopamine d(2) receptor binding in subregions of the thalamus in schizophrenia. Am. J. Psychiatry 161, 1016-1022. (Pubitemid 38735987)
252. Yasuno, F., Suhara, T., Ichimiya, T., Takano, A., Ando, T., and Okubo, Y. (2004b). Decreased 5-HT1A receptor binding in amygdala of schizophrenia. Biol. Psychiatry 55, 439-444. (Pubitemid 38338529)
253. Yi, S.J. and Johnson, K.M. (1990). Chronic cocaine treatment impairs the regulation of synaptosomal 3H-DA release by D2 autoreceptors. Pharmacol. Biochem. Behav. 36, 457-461. (Pubitemid 20223008)
254. Yoder, K.K., Hutchins, G.D., Morris, E.D., Brashear, A., Wang, C., and Shekhar, A. (2004). Dopamine transporter density in schizophrenic subjects with and without tardive dyskinesia. Schizophr. Res. 71, 371-375. (Pubitemid 39330515)
255. Zakzanis, K.K. and Hansen, K.T. (1998). Dopamine D2 densities and the schizophrenic brain. Schizophr. Res. 32, 201-206.
256. Zubieta, J.K., Taylor, S.F., Huguelet, P., Koeppe, R.A., Kilbourn, M.R., and Frey, K.A. (2001). Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects. Biol. Psychiatry 49, 110-116. (Pubitemid 32119504)